Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

October 24, 2023

Orthotopic vs. Subcutaneous: Unpacking the Strengths and Limitations of Tumor Model Implantation Sites

The scientific community has long appreciated the importance of in vivo tumor models for understanding cancer biology and testing therapeutic strategies. Two popular methods for tumor implantation in these models are orthotopic and subcutaneous implantation. Both have their advantages, and the choice often depends on the specific goals of a study. In this post, we'll delve deep into the benefits of each method to guide researchers in their decision-making process.

Model Spotlight: Breast Cancer Clinical Update and Preclinical Plan

Based on the American Cancer Society 2026 estimates and survival statistics, as of October 2026, developments in antibody-drug conjugates (ADCs), ...

Read more +

Advancing Preclinical Research in Gynecologic Cancers

Gynecologic cancers, including endometrial and ovarian cancers, remain areas of high unmet need. Advances in targeted therapy, immunotherapy, ...

Read more +

History of CAR T-cells and Their Continued Use in Hematological Malignancies to Advance Next-Generation Therapies

CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...

Read more +

Get Started

Contact Us Today!

If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.